Marina Chiara Garassino to Polymorphism, Single Nucleotide
This is a "connection" page, showing publications Marina Chiara Garassino has written about Polymorphism, Single Nucleotide.
Connection Strength
0.081
-
Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013; 8(4):e59981.
Score: 0.062
-
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep. 2015 Nov 17; 5:16331.
Score: 0.019